Oral epithelial cells discriminate between pathogenic and non-pathogenic stimuli, and only induce an inflammatory response when they are exposed to high levels of a potentially harmful microorganism. The pattern recognition receptors (PRRs) in epithelial cells that mediate this differential response are poorly understood. Here, we demonstrate that the ephrin type-A receptor 2 (EphA2) is an oral epithelial cell PRR that binds to exposed β -glucans on the surface of the fungal pathogen Candida albicans. Binding of C. albicans to EphA2 on oral epithelial cells activates signal transducer and activator of transcription 3 and mitogen-activated protein kinase signalling in an inoculum-dependent manner, and is required for induction of a proinflammatory and antifungal response. EphA2 -/mice have impaired inflammatory responses and reduced interleukin-17 signalling during oropharyngeal candidiasis, resulting in more severe disease. Our study reveals that EphA2 functions as a PRR for β -glucans that senses epithelial cell fungal burden and is required for the maximal mucosal inflammatory response to C. albicans.
O ral epithelial cells are continuously exposed to a multitude of antigens derived from food and the resident bacterial and fungal microbiota. They must be able to discriminate between pathogenic and non-pathogenic stimuli so that an inflammatory response is induced only when the epithelial cells are exposed to high levels of a potentially harmful microorganism. The interaction of oral epithelial cells with the fungus Candida albicans provides an example of this paradigm. As part of the normal microbiota of the gastrointestinal and reproductive tracts of healthy individuals 1 , this organism elicits a minimal epithelial cell response during commensal growth, when a low number of organisms is present. However, when local or systemic host defences are weakened, C. albicans can proliferate and cause oropharyngeal candidiasis (OPC), an infection that is highly prevalent in patients with human immunodeficiency virus/AIDS, diabetes and iatrogenic or autoimmune-induced dry mouth 2 . When OPC occurs, oral epithelial cells are activated to induce a proinflammatory response that plays a central role in limiting the extent of infection. For example, mice with an oral epithelial cell-specific defect in interleukin (IL)-17 receptor signalling or production of β -defensin 3 are highly susceptible to OPC and unable to resolve the infection 3 .
How oral epithelial cells discriminate between C. albicans when it grows as a commensal organism versus an invasive pathogen is incompletely understood. The fungus can interconvert between ovoid yeast and filamentous hyphae. C. albicans yeasts are poorly invasive and weakly stimulate epithelial cells to release proinflammatory cytokines and host defence peptides (HDPs). In contrast, hyphae avidly invade epithelial cells and strongly stimulate the production of cytokines and HDPs [4] [5] [6] . Mucosal epithelial cells express a variety of pattern recognition receptors (PRRs) that can potentially recognize C. albicans 7 . These cells also express nonclassical receptors such as the epidermal growth factor receptor (EGFR), HER2 and E-cadherin that can recognize C. albicans hyphae [8] [9] [10] . However, relatively little is known about PRRs in oral epithelial cells, even though these cells constitute a key barrier to mucosal infection.
Results
EphA2 is activated by fungal β-glucans. EphA2 is a receptor tyrosine kinase that induces both endocytosis and cytokine production by host cells 11, 12 . We investigated the hypothesis that EphA2 functions as an epithelial cell receptor for C. albicans. By confocal microscopic imaging of intact oral epithelial cells infected with C. albicans, we observed that EphA2 accumulated around yeast-phase cells after 15 min of infection and hyphae after 90 min ( Fig. 1a,b , Supplementary Fig. 1 ). To ascertain whether C. albicans activates EphA2, oral epithelial cells were infected with yeast-phase C. albicans cells and the extent of EphA2 phosphorylation was analysed over time. EphA2 phosphorylation increased above basal levels within 15 min postinfection, when the organisms were still in the yeast phase ( Fig. 1c, Supplementary Fig. 2 ). EphA2 phosphorylation also remained elevated after 60 and 90 min of infection, when the organisms had formed hyphae. When epithelial cells were incubated for 15 min with either yeast-or hyphal-phase organisms, EphA2 phosphorylation was stimulated to the same extent, indicating that both forms of the organism can activate the receptor ( Fig. 1d, Supplementary Fig. 2) .
To determine the specificity of EphA2 signalling, we analysed whether EphA2 phosphorylation could be induced by different microbial stimuli, including bacteria (Staphylococcus aureus, Escherichia coli), a clinical mucosal C. albicans isolate (529L), a yeast-locked C. albicans mutant (efg1/cph1), a non-invasive C. albicans mutant (als3/ssa1), a candidalysin-deficient C. albicans mutant (ece1) and different fungal species (Candida glabrata, Saccharomyces cerevisiae). Although neither S. aureus nor E. coli stimulated the phosphorylation of EphA2 ( Supplementary Fig. 3 ), all fungi tested induced phosphorylation of this receptor within 15 min of infection ( Fig. 1e , Supplementary Fig. 4 ), suggesting that EphA2 is activated by a conserved fungal cell wall component. To test this possibility, we analysed EphA2 activation by β -glucan and mannan, which are present in the cell walls of many fungi. Both particulate β -glucan (zymosan) and soluble β -glucan (laminarin) stimulated EphA2 phosphorylation after 15 and 30 min, and this phosphorylation NATuRE MicROBiOlOgy returned to basal levels by 60 min (Fig. 1f ,g, Supplementary  Fig. 5 ). Heat-killed C. albicans yeasts, which have increased surface exposed β -glucan 13 , also induced transient EphA2 activation ( Fig. 1h, Supplementary Fig. 5 ). By contrast, mannan, another cell wall component, failed to induce detectable EphA2 phosphorylation ( Supplementary Fig. 6 ).
To ascertain whether EphA2 interacts directly with β -glucans, we used an enzyme-linked immunosorbent assay (ELISA) to analyse the binding of recombinant EphA2 to potential ligands. As expected, EphA2 bound to its natural ligand, ephrin A1 (EFNA1) ( Fig. 1i ). EphA2 also bound to zymosan and laminarin, but not to mannan, in both the presence and absence of 10 mM EDTA, 
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indicating that binding to β -glucans is independent of Ca 2+ . EGFR, another epithelial cell receptor for C. albicans, did not bind to zymosan ( Supplementary Fig. 7 ). Consistent with the ELISA data, we found that recombinant EphA2 bound to intact yeast-phase C. albicans cells at regions of exposed β -glucan, as demonstrated by colocalization with Fc-Dectin-1 ( Fig. 1j ). EphA2 also bound to zymosan, and fluorescent-labelled zymosan bioparticles, as well as exposed β -glucan on other fungal pathogens, including Aspergillus fumigatus and Rhizopus delemar ( Supplementary Fig. 8 ).
EphA2 functions in the EGFR endocytosis pathway. C. albicans hyphae can invade oral epithelial cells by receptor-induced endocytosis 10 , and epithelial cell invasion is associated with fungal-induced epithelial cell damage 6 . To determine the biological significance of EphA2 activation, we analysed the effects of EphA2 short interfering RNA (siRNA), the small molecule tyrosine kinase inhibitor dasatinib (DAS) 14 and an EphA2 antagonist 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxybenzoic acid derivative (ANT) 15 on C. albicans invasion and damage of epithelial cells. Depletion of epithelial cell EphA2 by siRNA significantly inhibited the endocytosis of C. albicans ( Fig. 2a ) and attenuated the extent of fungal-induced epithelial cell damage ( Fig. 2b ). Transfection with EphA2 siRNA had no effect on cellular levels of the ephrin receptors EphA4 and EphB2, while EphB2 siRNA had no effect on cellular levels of EphA2 or epithelial cell endocytosis of C. albicans ( Supplementary Fig. 9 ). After verifying that DAS and ANT inhibited C. albicans-induced phosphorylation of EphA2 ( Supplementary Fig. 10 ), we determined that both inhibitors also inhibited epithelial cell endocytosis and damage ( Supplementary Fig. 11 ), but had no effect on C. albicans growth rate or hyphal elongation (Supplementary Table 1 ). The addition of EFNA1 to further stimulate EphA2 enhanced both endocytosis and damage ( Supplementary Fig. 11 ), indicating that the extent of EphA2 activation governs epithelial cell endocytosis of C. albicans and subsequent fungal-induced damage. EGFR signalling is crucial for inducing the endocytosis of C. albicans by oral epithelial cells, and there is cross-talk between EphA2 and EGFR in some cancer cells 8, 16, 17 . We analysed the relationship between EGFR and EphA2 signalling during the endocytosis of C. albicans and found that inhibition of EphA2 with either DAS or ANT, and inhibition of EGFR with gefitinib 8 , reduced the endocytosis of C. albicans by a similar amount ( Fig. 2c ). Simultaneous inhibition of both EphA2 and EGFR did not decrease endocytosis further. Also, EphA2 depletion with siRNA and inhibition of EphA2 signalling with DAS or ANT blocked C. albicans-induced EGFR phosphorylation ( Fig. 2d , Supplementary Fig. 12 ), while inhibition of EGFR with gefitinib decreased EphA2 phosphorylation after 60 min ( Fig. 2e , Supplementary Fig. 12 ). Collectively, these results suggest that a reciprocal interaction between EphA2 and EGFR governs the endocytosis of C. albicans.
EphA2 signalling is required for epithelial cell production of cytokines and HDPs. Contact with C. albicans yeast cells activates multiple signalling pathways in oral epithelial cells, including mitogen-activated kinase regulated kinase (MEK) 1/2, p38 and NF-κ B 18 . We investigated whether EphA2 might function as a receptor that activates these signalling pathways. We determined that C. albicans stimulated the phosphorylation of MEK1/2 and p38-mediated phosphorylation of the c-Fos transcription factor within 30 min of infection ( Fig. 2f , Supplementary Fig. 13 ). The phosphorylation of these proteins was maintained for at least 90 min and was inhibited by treatment of epithelial cells with EphA2 siRNA, DAS or ANT ( Fig. 2f , Supplementary Fig. 13 ). Although C. albicans stimulated phosphorylation of the p65 subunit of NF-κ B, this phosphorylation was not inhibited by DAS or ANT, suggesting that NF-κ B activation is induced by a receptor other than EphA2 ( Supplementary Fig. 13 ). One candidate receptor is the dectin-1 β -glucan receptor, which we determined was expressed on the surface of both the OKF6/ TERT-2 oral epithelial cell line and desquamated human buccal epithelial cells ( Supplementary Fig. 14) . We found that a neutralizing dectin-1 monoclonal antibody inhibited C. albicans-induced activation of p65 ( Fig. 2g , Supplementary Fig. 15 ), but had no effect on the phosphorylation of EphA2 ( Supplementary Fig. 16 ). These results suggest that during the epithelial cell response to C. albicans infection, dectin-1 is necessary for induction of NF-κ B signalling, whereas EphA2 is required for activation of the MEK1/2 and p38 signalling pathways.
To investigate EphA2 signalling induced by β -glucan alone, we analysed the response of epithelial cells to zymosan. While zymosan strongly activated MEK1/2 phosphorylation at 15 and 30 min, phosphorylation returned to basal levels by 60 min (Fig. 2h , Supplementary Fig. 17 ). Also, zymosan did not induce detectable c-Fos or p65 phosphorylation over the 90-min duration of the experiment ( Fig. 2h , Supplementary Fig. 17 ). Exposure of oral epithelial cells to either live C. albicans in the presence of the EGFR inhibitor or heat-killed C. albicans alone induced a similar response-transient EphA2 and MEK1/2 phosphorylation ( Fig. 2i ,j, Supplementary Fig. 18 ). Thus, EGFR and factor(s) expressed by live C. albicans are required to sustain EphaA2 and MEK1/2 signalling.
By secreting proinflammatory cytokines and HDPs, oral epithelial cells are vital for limiting fungal proliferation during OPC 19, 20 . The production of many of these factors is governed by the transcription factor signal transducer and activator of transcription 3 (Stat3) 19, 21 . We hypothesized that the interaction of C. albicans with EphA2 in oral epithelial cells would activate Stat3 and stimulate production of proinflammatory cytokines and HDPs. To test this, we determined the effects of EphA2 siRNA, DAS and ANT on Stat3 phosphorylation in epithelial cells. By both immunoblotting and ELISA, we found that C. albicans stimulated Stat3 phosphorylation within 15 min of infection and that blocking EphA2 with siRNA, DAS or ANT reduced C. albicans-induced Stat3 phosphorylation to basal levels ( Fig. 3a,b , Supplementary Fig. 19 ). Although exposure to zymosan induced Stat3 phosphorylation within 15 min, this phosphorylation was transient, returning to basal levels after 30 min ( Fig. 3c , Supplementary Fig. 19 ). Treatment with DAS or ANT inhibited zymosan-induced activation of Stat3 ( Supplementary  Fig. 20 ). However, blockade of dectin-1 had no effect on Stat3 activation induced by either C. albicans or zymosan ( Supplementary  Fig. 20 ), suggesting that EphA2 is the primary β -glucan receptor that activates this transcription factor.
By inhibiting EphA2 signalling with DAS or ANT, or Stat3 signalling with S31-201 22 , we found that the EphA2-Stat3 axis regulates C. albicans-induced messenger RNA expression of the chemokines Ccl20 and Ccl3 and the alarmin S100a8 in vitro ( Fig. 3d ). It also governs the secretion of human β -defensin 2 (hBD2) ( Fig. 3e,f) . Although inhibiting EphA2 with siRNA, DAS or ANT reduced Il8 mRNA expression and secretion of IL-8, IL-1α , IL-1β and CCL20, inhibition of Stat3 did not ( Fig. 3d,f) . Thus, these responses are induced by EphA2 independently of Stat3. Treatment of epithelial cells with DAS or ANT did not inhibit production of IL-8 induced by TNF-α and IL-17 ( Supplementary Fig. 21 ), indicating that these inhibitors only blocked the epithelial cell response to certain stimuli.
The addition of zymosan to the epithelial cells did not induce secretion of IL-8 or hBD2 ( Supplementary Fig. 22 ), suggesting that although β -glucan-induced EphA2 activation is required to prime epithelial cells, a second signal is necessary to prolong EphA2 activation and stimulate cytokine and HDP release. Dectin-1, another β -glucan receptor 23, 24 , played a limited role in the epithelial cell response to C. albicans; an anti-dectin-1 antibody had no effect on the release of hBD2, IL-1α or IL-1β by infected epithelial cells, although it did cause a modest reduction in IL-8 release (Fig. 3f ).
We investigated whether the extent of EphA2 activation governed the epithelial cell response to infection with different inocula of C. albicans. We found that while there was a gradual increase in the extent of EphA2 phosphorylation as the multiplicity of infection (MOI) increased from 0.1 to 5 organisms per epithelial cell, EphA2 phosphorylation dramatically increased at an MOI of 10 ( Fig. 4a , Supplementary Fig. 23 ). Low-level phosphorylation of MEK1/2 was also stimulated by C. albicans yeast at an MOI of 0.1 to 1, whereas phosphorylation increased exponentially at MOIs of 5 and 10 ( Fig. 4a, Supplementary Fig. 23 ). Phosphorylation of EphA2 was blocked by DAS and ANT at all MOIs ( Supplementary Fig. 23 ). The increased phosphorylation of EphA2 and MEK1/2 at high MOIs corresponded with enhanced secretion of IL-8 and hBD2 (Fig. 4b) . Thus, while low inocula of C. albicans induce modest EphA2 activation and a minimal inflammatory response, higher inocula highly activate EphA2, leading to a strong inflammatory response.
EphA2 signalling contributes to the host defence against OPC. To determine the biological significance of EphA2 as an oral mucosal β -glucan receptor for C. albicans in vivo, we induced OPC in otherwise immunocompetent EphA2 -/mice 25, 26 . After 1 d of infection, the EphA2 -/mice had a significantly higher oral fungal burden than 
the wild-type mice (Fig. 5a ). The oral tissues of EphA2 -/mice contained lower levels of CCL3, CXCL1/KC, IL-1β , IFN-γ and IL-17A, and higher levels of CCL2 and the cell damage-associated alarmin IL-1α , relative to the wild-type mice (Fig. 5b) . The levels of TNF-α , CCL4 and vascular endothelial cell growth factor in the oral tissues were similar between the EphA2 -/and the wild-type mice ( Fig. 5b , Supplementary Fig. 24 ). The severity of OPC in the EphA2 -/mice was increased further when they were immunosuppressed with lowdose triamcinolone (7 mg per kg). After 4 d of infection, these mice had greater weight loss and much higher oral fungal burden relative to wild-type mice (Fig. 5c,d) . We also tested the effects of inhibiting EphA2 with DAS in wild-type mice that were immunosuppressed with higher-dose triamcinolone (15 mg per kg). Mice that received DAS had greater weight loss ( Supplementary Fig. 25 ) and higher oral fungal burden relative to the animals that received the vehicle control ( Fig. 5e ). Histopathological analysis of the tongues of DAStreated mice confirmed that inhibition of EphA2 signalling resulted in larger fungal lesions and deeper tissue invasion ( Supplementary  Fig. 25 ). Mice treated with DAS also had greater fungal dissemination to the liver, suggesting that EphA2 is required for maintaining the epithelial barrier function of the gastrointestinal tract ( Fig. 5f ). When the fungal lesions on the tongues of the vehicle control mice were incubated with Fc-Dectin-1, many of the fungal cells were stained, indicating that β -glucan is exposed on the fungal surface during OPC ( Fig. 5g, Supplementary Fig. 26 ). Consistent with our in vitro results, we found that C. albicans infection of the vehicle control mice induced strong Stat3 phosphorylation in the oral epithelium, and this phosphorylation was reduced by treatment with DAS ( Supplementary Fig. 25 ). Administration of DAS also reduced Il17a mRNA expression in the oral tissues by 350-fold, Il22 mRNA by 1,000-fold, S100a8 mRNA by ninefold and Defb3 mRNA by sevenfold (Fig. 5h ). Collectively, these results indicate that EphA2 signalling is necessary for a maximal IL-17 response during OPC. Thus, EphA2 is a key regulator of the host inflammatory response to C. albicans that limits fungal proliferation during oral infection.
Discussion
The data presented herein indicate that EphA2 is a non-classical receptor for β -glucans that plays a vital role in sensing the presence of C. albicans yeast and hyphae in the oral cavity. While EphA2 contributes to receptor-induced endocytosis of the organism, this function is overshadowed by the central role of EphA2 in sensing the presence of high levels of fungal β -glucans and activating MAPKs and Stat3, thereby stimulating epithelial cells to produce proinflammatory cytokines and HDPs. In vivo, β -glucan recognition of invading fungi via EphA2 is also required for the production of IL-17, IL-22 and β -defensin 3, which are essential for resistance to OPC 20, 27, 28 . Thus, our data support the model that EphA2 recognizes β -glucans expressed by pathogenic fungi and thereby primes epithelial cells to respond appropriately and prevent OPC when the fungal inoculum increases above threshold levels (Fig. 6 ). The finding that EphA2 binds to β -glucans of other fungi, such as C. glabrata, A. fumigatus and R. delemar, suggests that this receptor also senses the presence of these organisms and induces specific host responses.
Methods
Ethics statement. All animal work was approved by the Institutional Animal Care and Use Committee of the Los Angeles Biomedical Research Institute. Table 2 ) were grown as described previously 9 . The OKF6/TERT-2 oral epithelial cell line (provided by Jim Rheinwald, Dana-Farber/ Harvard Cancer Center, Boston, MA) 29 was grown as described 9, 29 . OKF6/TERT-2 cells were authenticated by RNA-Seq 3 , and tested for mycoplasma contamination.
Fungal strains, cell lines and reagents. The strains used in the experiments (listed in Supplementary
To determine the effects of the various inhibitors, the host cells were treated for 1 h before stimulation or infection with 2.5 µ M dasatinib 30 , 400 µ M EphA2 antagonist, a 2,5-dimethylpyrrolyl benzoic acid derivative 15, 31 , 50 µ M Stat3 inhibitor S31-201 32 , 1 µ M gefitinib 16 and 3 µ g per ml dectin-1 monoclonal antibody (R&D Systems) 33 .
In other experiments, the cells were stimulated with 50 µ g per ml depleted zymosan (InvivoGen, San Diego, CA, USA), 50 µ g per ml mannan (Sigma-Aldrich, St. Louis, MO, USA) or 50 µ g per ml laminarin (InvivoGen). To deplete the OKF6/TERT-2 cells of EphA2, they were transfected with random control siRNA (Santa Cruz Biotechnology, Dallas, TX, USA; sc-37007), EphA2 siRNA (Santa Cruz Biotechnology; sc-29304) or EphB2 siRNA (Santa Cruz Biotechnology; sc-39949) with Lipofectamine 2000 (Invitrogen, Waltham, MA, USA) following the manufacturer's instructions, as described previously 16 .
Confocal microscopy. The accumulation of EphA2 around C. albicans was visualized by confocal microscopy using a slight modification of our previously described methods 34 . Oral epithelial cells were infected with 2 × 10 5 yeast organisms of a wild-type C. albicans strain expressing green fluorescent protein (GFP). After 15 and 90 min, the cells were fixed in 3% paraformaldehyde (wt/vol), blocked with 10% BSA (vol/vol) and incubated with antibodies against total EphA2 (Cell Signaling, Danvers, MA, USA; #6997) followed by an AlexaFluor 568-labelled goat anti-rabbit antibody. The cells were then imaged by confocal microscopy, and the final images were generated by stacking optical sections along the z axis. The binding of recombinant EphA2 (BioLegend, San Diego, CA, USA) and Fc-hDectin-1a (InvivoGen) to fungal cells was visualized similarly.
Flow cytometry. Human buccal epithelial cells were isolated from healthy donors by gentle scraping of the oral cavity. The cells were suspended in DMEM + 10% FBS for 1 h and then washed with HBSS. Next, they were incubated with a Dectin-1 antibody (R&D Systems; #MAB1859) followed by anti-mouse AlexaFluor 488 Ab. Control cells were incubated in a similar concentration of mouse IgG (Abcam, Inc., Cambridge, UK). The fluorescence of the cells was determined by flow cytometry, analysing at least 10,000 cells per condition. The acquired events were plotted using forward-scatter area versus side-scatter area and the gate was set to exclude cellular debris. The remaining population was plotted using FL1-Height (AlexaFluor 488) and displayed as a histogram. The surface expression of dectin-1 on OKF6/TERT-2 cells was analysed similarly.
Detection of protein phosphorylation. OKF6/TERT-2 cells in 24-well tissue culture plates were infected with 1 × 10 6 C. albicans for various times as described previously 16 . Next, the cells were rinsed with cold HBSS containing protease and phosphatase inhibitors and removed from the plate with a cell scraper. After the cells were collected by centrifugation, they were boiled in sample buffer. The lysates were separated by SDS-PAGE, and the phosphorylated proteins were detected by immunoblotting with phospho-specific antibodies, including anti-phospho-EphA2 (Cell Signaling; #6347), anti-phospho-Stat3 (Cell Signaling; #9134), anti-phosphoc-Fos (Cell Signaling; #5348), anti-phospho-MEK1/2 (Cell Signaling; #9154) and anti-phospho-p65 (Cell Signaling; # 3033).The blots were then stripped, and total protein levels and β -actin were detected by immunoblotting with appropriate antibodies against EphA2 (Cell Signaling; #6997), EphB2 (Cell Signaling; #83029), EphA4 (Santa Cruz Biotechnology; sc-365503), Stat3 (Cell Signaling; # 12640), c-Fos (Cell Signaling; # 4384), MEK1/2 (Cell Signaling; # 9122), p65 (Cell Signaling; # 8242) and β -actin (Cell Signaling; # 3700). The blots were developed using enhanced chemiluminescence and imaged with either a FluorChem 8900 (Alpha Innotech, San Leandro, CA, USA) or C400 (Azure Biosystems, Dublin, CA, USA) digital imager.
Stat3 ELISA. To quantify the phosphorylation of Stat3, OKF6/TERT-2 cells in 96-well tissue culture plates were treated with inhibitors for 1 h and then infected with 3 × 10 5 C. albicans cells for different time periods. Next the epithelial cells were permeabilized, and the phosphorylation of Stat3 was measured by an ELISA for phospho-Ser727 (LSBio, Seattle, WA, USA) following the manufacturer's instructions.
Measurement of host cell endocytosis.
The endocytosis of C. albicans by oral epithelial cells was quantified as described previously 9 . OKF6/TERT-2 cells were grown to confluency on fibronectin-coated circular glass coverslips in 24-well tissue culture plates and then infected for 120 min with 2 × 10 5 yeast-phase C. albicans cells per well, after which they were fixed, stained and mounted inverted on microscope slides. The coverslips were viewed with an epifluorescence microscope, and the number of endocytosed organisms per high-power field was determined, counting at least 100 organisms per coverslip. The effects of the inhibitors and EFNA1 (Acro Biosystems, Newark, DE, USA) on endocytosis were determined as described above.
The inhibitors were added to the host cells 60 min before the fungal cells, and they remained in the medium for the entire incubation period.
Host cell damage assay. The extent of host cell damage caused by the C. albicans was measured using our standard 51 Cr release assay 9, 35 . Briefly, OKF6/TERT-2 cells were grown to confluence in 96-well tissue culture plates, loaded with Na 2 51 CrO 4 (MP Biomedicals, Santa Ana, CA, USA) overnight and then infected with 3 × 10 5 cells of the C. albicans. Uninfected epithelial cells were processed in parallel as a negative control. After an 8-h incubation, the amount of 51 Cr that had been released into the medium and that remained associated with the cells was measured by γ -counting. After correcting for well-to-well differences in the incorporation of NATuRE MicROBiOlOgy 51 Cr, the percent specific release of 51 Cr was calculated using the following formula: (experimental release− spontaneous release)/(total incorporation− spontaneous release). Experimental release was the amount of 51 Cr released into the medium by cells infected with C. albicans. Spontaneous release was the amount of 51 Cr released into the medium by uninfected host cells. Total incorporation was the sum of the amount of 51 Cr released into the medium and remaining in the host cells. Each experiment was performed three times in triplicate.
RNA isolation and real-time PCR.
Total RNA was isolated and real-time PCR was performed as previously described 36 . The host cell RNA was extracted using the Ribopure Yeast Kit (Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions. The mRNA levels were measured by real-time PCR using the primers listed in Supplementary Table 3 . The relative transcript level of each gene was normalized to GAPDH by the 2 -ΔΔCT method.
Measurement of hBD2 secretion. OKF6/TERT-2 cells in 24-well tissue culture plates were pretreated with inhibitors and then infected with 1 × 10 6 C. albicans for 20 h. The supernatants were collected, clarified by centrifugation and then stored at − 80 °C. At a later time, the levels of hBD2 were determined by ELISA (Peprotech, Rocky Hill, NJ, USA) following the manufacturer's instructions.
Cytokine and chemokine measurements in vitro.
Cytokine levels in culture supernatants were determine as previously described 37 . Briefly, OKF6/TERT-2 cells in a 96-well plate were infected with C. albicans at an MOI of 5 or stimulated with a combination of 50 ng per ml IL-17 A and 0.5 ng per ml TNF-α (both from Peprotech). After 8 h of infection, the supernatant was collected, clarified by centrifugation and stored in aliquots at − 80 °C. The concentration of inflammatory cytokines and chemokines in the medium was determined using the Luminex multiplex assay (R&D Systems). Also, the concentration of IL-8 in the supernatants was determined by ELISA (R&D Systems). Each condition was tested in three independent experiments.
EphA2-binding ELISA. A polystyrene 96-well plate was coated with 50 µ g carbohydrates (laminarin, zymosan or mannan), 2 µ g EFNA1 (positive control) or 50 µ g BSA overnight at 20 °C and then blocked with non-fat dry milk for 1 h. After the plate was extensively washed, 100 µ g per ml recombinant EphA2 (Gln25-Asn534-6xHis; BioLegend) was added to each well and the plate was incubated for 2 h at 37 °C. The wells were rinsed and then incubated for 1 h at 37 °C with 1 µ g per ml anti-His-HRP monoclonal antibody, followed by rinsing and addition of the colour reagent as recommended by the manufacturer (R&D Systems). After 5 min, stop solution was added and the optical density at 450 nm was determined.
In a different approach, zymosan-coated wells were incubated with recombinant EphA2, EGFR, Met 1-Ser 645-6xHis or BSA (all at 100 µ g per ml, ThermoFisher, Waltham, MA, USA) and processed as described above.
Mouse model of OPC. EphA2 −/− mice (backcrossed to the C57BL/6 background 26 ) were provided by A. Wayne Orr, LSU Health Sciences Center, Shreveport, LA. C57BL/6 controls were obtained from The Jackson Laboratory. EphA2 −/− and C57BL/6 control mice were cohoused for 1 week before the experiments. Six-week-old male EphA2 −/− and age-and sex-matched C57BL/6 mice were used in a mouse model of OPC 16, 25 . When immunocompromised EphA2 −/− and C57BL/6 mice were used, triamcinolone (7 mg per kg) was administered subcutaneously on days − 1, 1 and 3. For inoculation, the animals were sedated, and a swab saturated with 10 6 C. albicans cells was placed sublingually for 75 min 25 . Immunocompetent mice were inoculated similarly, except that the swab was saturated with 2 × 10 7 organisms 16 . The immunocompromised and immunocompetent mice were sacrificed after 1 day and 4 days of infection, respectively. The mice were euthanized, and their tongues were harvested. The tongues were weighed, homogenized and quantitatively cultured. To determine cytokine and chemokine protein concentrations during OPC, the homogenates were prepared as previously described 38 and the proinflammatory mediators were measured using a multiplex bead array assay (R&D Systems).
The effect of DAS on the severity of OPC was determined in triamcinolonetreated (15 mg per kg) male BALB/C mice. The mice were randomized before dasatinib or vehicle treatment. The mice were fed an oral solution of either dasatinib (10 mg per kg per day) of the vehicle control (0.4% DMSO), twice a day, administered at 0.05 ml per mouse starting on day − 1 relative to infection. At day 4, the tongue and attached tissues were harvested and divided by two. One half was weighed, homogenized and quantitatively cultured. The other half was snap frozen in optimal cutting temperature (OCT); 2-μ m-thick sections were cut with a cryostat and fixed with cold acetone. To detect phosphorylation of Stat3, the cryosections were rehydrated in PBS and then blocked with 10 % BSA. Sections were stained with a phospho-Stat3 antibody (Cell Signaling; #9134), Fc-Dectin-1 (InvivoGen) and an AlexaFluor 568-labelled anti-Candida antibody, followed by a secondary antibody and imaged by confocal microscopy. To enable comparison of fluorescence intensity between slides, the same image acquisition settings were used for each experiment. For histopathology, additional cryosections were prepared and stained with periodic acid-Schiff stain.
In all of the mouse studies, the animals were randomly assigned to the different treatment groups. The researchers were not blinded to the experimental groups because the primary endpoint (oral fungal burden) was an objective measure of disease severity. Prior data indicated that the difference in oral fungal burden in the mouse model of OPC within each subject group was normally distributed with a standard deviation 0.2 log colony forming units per g tissue. If the true difference in the mean response of matched pairs is 0.5, the use of four pairs of mice would be sufficient to reject the null hypothesis with a probability (power) > 0.9. The type I error probability associated with this test of this null hypothesis is 0.05.
Statistics.
At least three biological replicates were performed for all in vitro experiments unless otherwise indicated. Data were compared by Mann-Whitney, unpaired Student's t test or Holm-Sidak method using GraphPad Prism (v. 6) software. P values < 0.05 were considered statistically significant.
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